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Thymic-derived naturally occurring regulatory T cells (tTreg) are crucial for maintaining 
peripheral immune homeostasis. They play a crucial role in preventing autoimmunity 
and maintaining organ transplant without requiring immunosuppression. Cellular metab-
olism has recently emerged as an important regulator of adaptive immune cell balance 
between Treg and effector T  cells. While the metabolic requirements of conventional 
T cells are increasingly understood, the role of Treg cellular metabolism is less clear. The 
continuous exposure of metabolites and nutrients to the human liver via the portal blood 
flow influences the lineage fitness, function, proliferation, migration, and survival of Treg 
cells. As cellular metabolism has an impact on its function, it is crucial to understand the 
metabolic pathways wiring in regulatory T cells. Currently, there are ongoing early phase 
clinical trials with polyclonal and antigen-specific good manufacturing practice (GMP) 
Treg therapy to treat autoimmune diseases and organ transplantation. Thus, enhancing 
immunometabolic pathways of Treg by translational approach with existing or new drugs 
would utilize Treg cells to their full potential for effective cellular therapy.
Keywords: regulatory T  cells, microenvironment, liver, Treg plasticity, function, immunometabolism, good 
manufacturing practice Treg, cell therapy
ReGULATORY T CeLLS AND PeRiPHeRAL SeLF-TOLeRANCe
Regulatory T (Treg) cells are a subset of CD4+ T cells that maintain peripheral immune homeostasis 
by suppressing a range of untoward immune responses thus maintaining the balance between 
immune activation and tolerance (1). Sakaguchi and colleagues first reported Treg cells in 1995 via 
adoptive transfer studies, which demonstrated the subset of CD4+ T cells expressing the interleu-
kin-2 (IL-2) receptor alpha chain, CD25, preventing autoimmune diseases (2) (Figure 1). Around 
5–10% of CD4+ T cells are CD25+, they are able to maintain peripheral immunologic self-tolerance 
by suppressing self-reactive lymphocytes (1, 2). Subsequently, Seddiki (3) and Liu (4) reported that 
low level expression of the IL-7 receptor, CD127, inversely correlated with FoxP3 expression and 
Treg cell’s suppressive function due to the repressor function of FoxP3. FoxP3 is a master tran-
scription factor and regulator of Treg phenotype and function (5). Mutations in the FoxP3 gene 
cause defective development of CD4+CD25+ Treg cells, leading to IPEX syndrome (immunodys-
regulation, polyendocrinopathy, enteropathy, X-linked genetic trait) (6). Lymphoproliferation and 
multiorgan autoimmunity in scurfy mutant mice is caused by the absence of FoxP3 (7). FoxP3 is 
regulated by conserved non-coding DNA sequences (CNS) 1–3. CNS2 is required for FoxP3 expres-
sion in the dividing Treg cell and CNS3 controls de novo Foxp3 expression and thymic Treg-cell 
FiGURe 1 | Regulatory T cells in tissue and blood compartments. The human liver is a hypoxic environment as the majority of blood flow is from the portal venous 
system. This leads to hypoxic induced factor 1-α (HIF-1α) activation, which subsequently enhances FoxP3 expression along with Th17 differentiation. Hypoxia leads 
to anaerobic glycolysis and extracellular lactic acid accumulation. Short-chain fatty acids (SCFAs) bind to the receptor GPCR43; long-chain fatty acids (LCFAs) bind 
to CD36, glutamine binds to ASCT2, and arginine binds to CAT2. Glucose transporter-1 (Glut-1) is poorly expressed on Treg cells compared with effector T cells. 
Liver Treg cells are mainly of an effector memory phenotype (RA−CCR7−). There is only minimal level of IL-2 present in the human liver compared with the blood, 
which restrict hepatic Treg function. Blood Treg-cell subsets are composed of effector memory (RA−CCR7−), central memory (RA−CCR7+), and naive (RA+CCR7+) 
phenotype. HIF-1α, Hypoxia-inducible factor 1α; HIF-1β, Hypoxia-inducible factor-1β; AhR, aryl hydrocarbon receptor; FA, Fatty acids; ARNT, Aryl Hydrocarbon 
Receptor Nuclear Translocator; mTOR, mammalian target of rapamycin; SCFA, short chain fatty acid; LCFA, long chain fatty acid; ASCT2, Alanine, serine, 
cysteine-preferring transporter 2; CAT, Cationic amino acid transporter; GPCR, G protein–coupled receptor.
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differentiation (8). Therefore, Treg cells are currently defined as 
CD4+CD25highCD127low/−FoxP3+ cells.
Treg cells are essential for maintaining peripheral tolerance by 
controlling autoreactive T  cells, which escape negative selection 
in the thymus (9). They can be broadly divided into two types; 
thymic-derived Treg (tTreg) cells and peripheral Treg (pTreg) 
cells (10). Strong T  cell receptor (TCR) signaling with CD28 
co-stimulation, just below the threshold for negative selection, 
promotes tTreg lineage commitment in the thymus (11). pTreg cells 
are generated in the periphery from populations of mature T cells 
under certain antigenic stimulating conditions; persistent weak 
TCR stimulation along with IL-2, transforming growth factor-β 
(TGF-β) or retinoic acid (RA) (12, 13). The DNA in tTregs is 
demethylated in the Treg-specific demethylated region (TSDR) in 
the FoxP3 enhancer, whereas the TSDR of pTregs is only partially 
demethylated (14). Although both tTreg and pTreg are difficult to 
distinguish phenotypically, both are thought to play an essential 
role in immune regulation (15), with tTreg cells controlling reac-
tivity toward self-antigens and pTreg cells controlling responses 
to antigen exposure in the periphery. Treg cells require IL-2 to 
maintain their function and survival. Because Treg cells do not 
make IL-2, they are dependent on IL-2 derived from other T cells 
(16). Treg cells are highly sensitive to IL-2, due to their constitu-
tively high expression of CD25 and amplified intracellular signal 
transduction downstream of the IL-2 receptor, phosphorylation of 
STAT5 to upregualte essential Treg functional gene such as CD25, 
FoxP3, and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) 
(17). Treg cells can therefore compete with conventional T cells for 
IL-2 as a mechanism to prevent unwanted immune responses (17).
Treg conduct their suppressive function via multiple mechanisms 
throughout different compartments of the body. Treg are therefore 
also equipped with various functional markers. In the context of 
liver disease, they constitutively express CTLA-4 (16, 18, 19), ecto-
nucleoside triphosphate diphosphohydrolase 1, CD39 (16, 20), and 
the intracellular immunosuppressive cytokine, IL-10 (16, 21).
Cytotoxic T  lymphocyte-associated antigen 4 is a target gene 
of FoxP3 (22), and activation of Treg results in upregulation of 
CTLA-4; its deficiency in mice leads to fatal lymphoproliferation 
and multiorgan lymphocyte infiltration (23, 24). CTLA-4 binds 
the ligands CD80 and CD86 on antigen-presenting cells (APCs) 
such as dendritic cells (DCs). Its mechanism has been reported 
as removal of these ligands from APC cell surface by trans-
endocytosis, which subsequently prevents the effective activa-
tion of naïve CD4+ T cells by APCs (25). CTLA-4-CD80/CD86 
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binding leads to upregulation of indoleamine 2,3-dioxygenase 
(IDO), which catabolizes tryptophan (Trp) into immunosup-
pressive kynurenines (26). CD39 on both human and murine 
Treg exert their function via generation of adenosine by the 
breakdown of adenosine triphosphate (ATP) and other extra-
cellular nucleotides, which then bind to adenosine 2A receptors 
expressed on effector T cells causing a rise in intracellular cyclic 
adenosine monophosphate, thus inhibiting proliferation of 
effector T cells (27).
iNTRAHePATiC MiCROeNviRONMeNT
The phenotype and function of Treg cells in circulatory and 
intrahepatic compartments is different as the intrahepatic 
microenvironment is hypoxic and enriched with cytokines 
and metabolic products (1) (Figure  1). Intrahepatic Treg cells 
respond to (i) engagement of the TCR with MHC Class II on 
APCs, (ii) the binding of CD28/CTLA-4 on cells with CD80/86 
on APCs, and (iii) the influence of cytokines from APC for their 
activation, survival, and differentiation (28, 29). We reported that 
the intrahepatic microenvironment is highly enriched with the 
pro-inflammatory cytokines IL-1β, IL-6, and IL-12 (16) from 
hepatic DCs but lacks the crucial Treg cell survival cytokine; IL-2 
(19). With the recent advances in research into the metabolism 
of individual immune cell including T cells, it is now realized that 
differentiation, survival, and function of Treg cells depends not 
only on TCR, co-stimulatory and cytokine signals but also on 
other signals in the environment, specifically the local milieu of 
oxygen, metabolites, and catabolites (30).
MeTABOLiC iNFLUeNCe ON PLASTiCiTY, 
FUNCTiON, SURvivAL, AND MiGRATiON 
OF Treg CeLLS
The human liver is uniquely situated to receive a blood supply from 
the portal venous system, which is enriched with metabolites 
and nutrients. Human liver has a dual blood supply, deriving 
70–80% of its blood, rich in nutrients, from the portal vein 
and the other 20–30%, rich in oxygen, from the hepatic artery 
(31). Thus, Treg and T effector cells reside in the hepatic micro-
environment with continuous exposure to metabolic signals 
(Figure  2). Resting T  cells require little energy generation or 
expenditure; however, upon activation, their energy needs 
increase substantially, and they utilize glucose, amino acids, and 
fatty acids (FAs) to meet this demand. Metabolic effects on Treg 
cells could either be via direct binding of metabolites to Treg 
or via changes in cytokines profiles in DCs, which take up and 
process these metabolites.
Glucose
Glucose is a critical fuel for Treg cell ATP generation, cell activa-
tion, and function. Glucose transporter-1 (Glut-1) levels are low 
in Treg cells compared with effector cells because FoxP3 limits 
Glut-1 expression through inhibition of Akt (36). Treg cells exhibit 
low to modest glycolysis compared with effector T cells along with 
elevated mTOR activity (37–39). Kishore and colleagues recently 
demonstrated that enzyme glucokinase (GCK)-dependent glyco-
lysis regulates Treg-cell migration as GCK promotes cytoskeletal 
rearrangements by associating with actin. Treg cells lacking this 
pathway were functionally suppressive but failed to migrate to 
skin allografts and inhibit rejection (40).
Fatty Acids
The colonic microbiota metabolizes complex carbohydrates 
and undigested dietary fibers to oligosaccharides and monosac-
charaides, which are then fermented to short-chain fatty acids 
(SCFAs); acetate, propionate, and butyrate (41). Free FAs can 
diffuse across the plasma membrane into the cytosol. FAs are cat-
egorized into groups based on the length of their aliphatic chain. 
SCFAs have 2–6 carbons; medium chain fatty acids (MCFAs) 
have 7–12 carbons; and long-chain fatty acids (LCFAs) have more 
than 12 carbons. SCFAs and MCFAs are absorbed directly into 
the blood via intestinal capillaries and travel through the portal 
vein. However, LCFAs are absorbed into the intestinal villi and 
reassembled again into triglycerides. The triglycerides are coated 
with cholesterol and protein (protein coat), forming chylomicron, 
which is carried via the lymphatics to drain into the systemic 
circulation (Figure 2). MCFAs and LCFAs are considered one of 
the most abundant components of the “Western diet” (42). The 
concentration of SCFAs is highest in the proximal colon where 
fermentation mostly occurs.
Short-Chain Fatty Acids
Short-chain fatty acids exert metabolic regulation by signal-
ing through metabolite- sensing G-protein-coupled receptors 
(GPCRs). GPCR43, or free fatty acid receptor 2, binds to SFCAs 
(43) (Figure 1). Immune cells such as Treg cells and DCs express 
GPR43, which bind SCFAs and promote their differentiation and 
function to maintain intestinal homeostasis (43). Regulation of 
colonic and pTreg-cell numbers also relies upon the expression of 
GPR103, a receptor for Niacin (vitamin B3), which is expressed 
on DCs, which promote Treg-cell differentiation (44, 45) 
(Figure 2). The SCFA, butyrate has been shown to inhibit histone 
deacetylase (HDAC) thereby enhancing histone acetylation in 
the FoxP3 promoter region to promote stable FoxP3 expression 
(45). Butyrate also promotes the extra-thymic induction of Treg 
cells via the intronic enhancer conserved non-coding sequence 
1 (46).
GPCR84 recognizes MCFAs. LCFAs are transported across the 
membrane by fatty acid translocase (or CD36) (47) or GPCR40 
(free FA receptor-1) (48) (Figure  1). The effect of LCFAs was 
studied recently by Haghikia and colleagues in EAE reporting 
that the addition of lauric acid (C12), to a culture of CD4+ T cells, 
not only increases the differentiation of Th1 and Th17 cells but 
also leads to a reduction in Treg cells (49).
Data on immunometabolism on tissue resident T cells are lim-
ited. Recent data from Pan and colleagues described that mouse 
CD8 tissue resident memory cells generated by viral infection of 
the skin differentially express high levels of molecules that medi-
ate lipid such as fatty acid-binding proteins 4 and 5. They then 
continued to link this finding with human psoriatic skin suggest-
ing the important role of FAs and their oxidative metabolism for 
tissue resident cells to mediate protective immunity (50).
FiGURe 2 | Gut–liver axis and metabolites flux toward the liver. Intrahepatic T cell (including Treg cells) lineage fitness, function, survival, and proliferation are 
influenced by signals from the antigen presenting dendritic cells (DCs) and cytokines. The T cell receptor (TCR) binding to the foreign antigen–MHC II complex and 
co-stimulation provided by CD80 and CD86 binding to the T cells CD28/CTLA-4 induces T cell activation or inhibition of its function. Cytokines secreted by the DCs 
determine the differentiation pathway of the activated CD4 T cell to different Th1/Th2/Th17 lineages or Treg-cell survival with contact-dependent mechanism with 
DCs CD80/86. IL-2 is secreted in the liver by activated T effector cells, and this is required for Treg-cell survival and suppressive function. Dietary SCFAs (acetate, 
propionic acid, and butyrate) and MCFAs arrive to the liver via the portal vein, but LCFAs are absorbed via intestinal lymphatics and drain back into the systemic 
circulation via the thoracic duct. The amino acids, Glu and Arg, and glucose are also absorbed via the portal venous system towards the liver. There is always a 
certain degree of gut leakiness and bacterial product such as lipopolysaccharide reaches to the liver, and they rapidly undergo phagocytosis by hepatic sinusoidal 
Kupffer cells, which function as a sinusoidal firewall of the liver (32). The liver is enriched with fat-soluble vitamins such as vitamins A and D. DCs express 
immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO), which transform Trp into kynurenine, which is then metabolized into other catabolites through the 
action of enzymes within the kynurenine pathway (26, 33, 34). Trp-derived catabolites can mediate the tolerogenic effects of IDO by inducing apoptosis of activated 
but not resting T cells (35). Folic acid binds to folic acid receptor (FR4) on the Treg cell and Niacin (vitamin B3) interacts with GPCR109 on DCs. Glu, glutamine; Trp, 
tryptophan; Arg, arginine; SCFA, short-chain fatty acid; MCFA, median chain fatty acid; LCFA, long-chain fatty acid.
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Investigating the role of SCFAs on human T cells is in its early 
stage. Peripheral blood mononuclear cells of healthy donors 
exposed to SCFAs, especially butyrate, reduced IL-6 levels and 
hence increased the differentiation of Treg cells over Th17 cells 
(51). Indeed, this is supported by the recent data from Schmidt 
et  al. suggesting that exposure to butyrate along with TGF-β1 
enhanced Foxp3 induction in human T cells to a greater extent 
than TGF-β1 alone (52).
Amino Acids
Amino acids and peptides are generated in the gut via the 
hydrolysis of endogenous and alimentary proteins by extracel-
lular proteases and peptidases derived from the pancreatic and 
other digestive enzymes and commensal bacteria residing in the 
gut. Amino acids can serve as sources for metabolites that enter 
into the metabolic tricarboxylic acid (TCA) cycle. In the context 
of T  cell biology, arginine (Arg), glutamine (Glu), and Trp are 
critical for efficient T cell function and proliferative responses.
Arg and Treg-Cell Proliferation
Metabolic activity is intimately linked to T cell function. Arg is 
transported to the cells by cationic transporters CAT1–4 (53) 
(Figure  1). BAZ1B, PSIP1, and Translin are also potential Arg 
sensors that promote T  cell survival (54). Intracellular Arg is 
metabolized by arginase 1 and nitric-oxide synthase 2. The human 
liver contains myeloid-derived suppressor cells, which consume 
and deplete extracellular Arg (55). Arg-depleted environments 
impair T cell proliferation.
Glu and Treg Survival, Proliferation
The amino acids leucine and Glu enter into T  cells via their 
transporter LAT1 (CD98 for leucine and ASCT2 for Glu) 
(Figure 1). Glu-deprived activated CD4 T cells differentiate into 
Treg cells rather than Th1 cells even in the presence of cytokines 
that would normally favor Th1 cell differentiation (56). Treg cells 
do not require LAT1 or ASCT2 for their differentiation in vitro 
(57). Treg-cell differentiation is favored during Glu depriva-
tion (56) via mTOR signaling (58). Both leucine and Glu are 
positive regulators of CD4 T  cell differentiation into Th1 and 
Th17 cells because absence of LAT1 expression impairs the dif-
ferentiation of these lineages (59), and elevated Glu levels favor 
Th1 and Th17  cell differentiation (57). Glu-derived metabolite 
α-ketoglutarate promotes Th1 differentiation through enhancing 
mTORC1 signaling (56).
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Trp and Treg-Cell Function
Dietary aryl hydrocarbon receptor (AhR) ligands absorbed via 
the gut have been shown to be involved in Th17 generation 
(60, 61). Trp, an essential amino acid derived from ingested pro-
teins, is one of the AhR ligands. On the other hand, IDO in DCs 
catabolizes Trp, resulting in localized Trp depletion. Trp-derived 
kyurenins are a crucial mechanism of Treg-cell suppression (62) 
(Figure  2). Thus, different metabolites at different stages have 
their own roles in T cell lineage differentiation.
vitamins and Treg Function
Treg-cell biology depends on vitamins A, D, B3 (Niacin), and 
B9. Fat-soluble vitamins, vitamin A, D, E, and K, are enriched 
in the human liver (Figure 2). Vitamin A, RA, has an important 
role in Treg-cell development and function in the gut via CD103 
DCs in the mesenteric lymph nodes (63). RA can also generate 
gut homing Treg cells (64). Vitamin B3, nicotinic acid, signals 
through GPCR109a and leads to expression of retinal dehydro-
genases in colonic DCs, which in turn induces Treg-cell differ-
entiation thus vitamin B3 promotes colonic Treg-cell generation 
(65). It is likely that these DC subsets may be present in the 
inflamed human liver via the portal vein (Figure 2). 1,25(OH)2 
vitamin D3 inhibits T effector cell proliferation, induces Foxp3 
expression, and enhances the suppressive activity of Treg cells 
(66). Folic acid, derived from vitamin B9, is required for DNA 
synthesis and repair. Human Treg cells express high level of 
folate receptor-4 (FR4) (67) and inhibit Treg-cell apoptosis (68) 
(Figure 2).
T Cell Migration and Metabolism
The majority of liver resident immune cells, including Treg 
cells, are normally observed within the hepatic portal tract and 
septum (interface hepatitis) and parenchyma (lobular hepatitis) 
depending on the local area of inflammatory response (69). We 
reported previously that the CXCR3–CXCL10 pathway is crucial 
for recruitment of blood Treg cells to the inflamed liver via 
the hepatic sinusoids (70) and the CCR6–CCL20 axis plays an 
essential role in the positioning of lymphocytes around the bile 
ducts (71). We have also shown that the survival of intrahepatic 
lymphocytes depends on VCAM1 expression on the bile ducts 
and VLA-4 expression on the lymphocytes (72). Once circulatory 
Treg cells are recruited via the sinusoids, their post-endothelial 
migration and positioning are influenced by integrin expres-
sion on the fibrous stromal framework in the liver and also the 
chemokines gradient (73). Some intrahepatic Treg cells may 
drain back to local draining portal lymph nodes, which drain 
the liver. In addition, the hepatic microenvironment is hypoxic, 
especially around the central vein region and there is a high level 
of lactate in the inflamed human liver. T effector cell migration is 
known to be highly dependent on aerobic glycolysis, and lactate 
seems to regulate their migration (74). Recent data suggested that 
glycolysis was instrumental for Treg migration and was initiated 
by pro-migratory stimuli via a PI3K–mTORC2-mediated path-
way culminating in induction of the enzyme GCK. Subsequently, 
GCK promoted cytoskeletal rearrangements by associating 
with actin. Treg cells lacking this pathway were functionally 
suppressive but failed to migrate to skin allografts and inhibit 
rejection suggesting that GCK-dependent glycolysis regulates 
Treg-cell migration (40).
ePiGeNeTiC CONTROL OF T CeLL 
MeTABOLiSM
Epigenetic mechanisms, such as histone modification, DNA 
methylation of CpG residues, and nucleosome repositioning, alter 
the accessibility of transcription factors and RNA polymerase to 
regulatory regions of the genome are important regulators of the 
immune cells and their metabolism.
Methylation
The stable expression of Foxp3, which is important for Treg cell’s 
suppressive function, is maintained via the demethylation of the 
TSDR (75, 76). However, pTreg cells show a lack of Treg-specific 
DNA hypomethylation, which correlates with Treg cell’s genetic 
signature (75). Stable Foxp3 requires DNA hypomethylation at 
FOXP3 CNS2 (76, 77).
Acetylation, HDAC inhibitor,  
and Metabolism
Epigenetic modifications influence the chromatin remodeling 
via acetylation; DNA methylation and histone modifications 
play a key role in the regulation of metabolic gene expression 
and cell differentiation, function, and recruitment. Histone 
acetylation by histone acetyl transferases allows gene expres-
sion and histone deacetylation by HDACs, which inhibits gene 
expression as well as regulating chromatin remodeling and 
functional transcription factors. Administration of an HDAC 
inhibitor (HDACi) in vivo increased Foxp3 gene expression, as 
well as the production and suppressive function of Treg cells. 
HDAC9 seems to be particularly important in regulating Foxp3-
dependent suppression. HDACi therapy in vivo enhanced Treg 
cell-mediated suppression and decreased the degree of inflam-
matory bowel disease (78). Thus, pharmacological inhibitors of 
HDAC have potential therapeutic benefits in autoimmunity. 
Their action may also be mediated via immunometabolism; 
for example, HDAC inhibition leads to the induction Treg-cell 
generation by butyrate (78). HDACis, such as trichostatin A, 
SAHA, butyrate, and valproic acid, lead to immunomodulation 
by upregulating Treg-cell programming and suppressing Th1/
Th17 programming (79) (Figure 3).
TRANSLATiONAL iMMUNOMeTABOLiSM 
OF ReGULATORY T CeLLS
Manipulation of metabolism to enhance Treg-cell function 
in autoimmune diseases is an exciting therapeutic avenue. 
Dysregulated effector T  cell responses and failure of T  regula-
tory cell suppression of these effector cells is a typical feature 
of autoimmunity. Repurposing of current metabolic drugs and 
exploring new targets to change immune balance is currently an 
attractive translational option for clinicians and scientists who 
aim to apply cell metabolism for patient benefit.
FiGURe 3 | Regulatory T cells are controlled by epigenetic mechanisms and T cell receptor (TCR) and interleukin-2 (IL-2) pathway. Histone acetylation facilitates 
FoxP3 gene expression and deacetylation inhibits gene expression. HDACi, such as butyrate, can lead to upregulation of the Treg-cell master regulatory gene, 
FoxP3, and enhance its function. TCR and IL-2 combined stimulation leads to PI3 kinase activation and subsequent downstream activation of mTOR signaling via 
Akt. Treg cells require lipogenic metabolism via the mevalonate pathway, which subsequently leads to upregulation of Treg-cell suppressive molecules cytotoxic 
T lymphocyte-associated antigen 4 (CTLA-4) and ICOS in mTORC1-dependent manner. HDAC, Histone deacetylase inhibitor; PI3K, phosphatidylinositol 3-kinase; 
Akt, Protein Kinase B; mTOR, mammalian target of rapamycin; GPCR, G protein–coupled receptor.
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Targeting Carbohydrate Metabolism
Although it is accepted that repression of Akt/mTOR, hypoxic 
induced factor 1-α (HIF-1α), and aerobic glycolysis is important 
for the efficient generation of blood Treg cells in vitro, clear evi-
dence how these pathways impact on blood and tissue resident 
Treg-cell development in  vivo is limited. Understanding these 
pathways, not only in the circulation but also at the tissue level 
is necessary to enhance Treg-cell metabolism and its subsequent 
function. Although Glut-1 expression is a critical factor in driving 
glycolysis in circulatory T effector cells, Treg cells’ function seems 
to be independently of Glut-1 (80).
HIF-1α Pathway
The hepatic environment in both inflammatory and autoimmune 
conditions is hypoxic as human liver receive only 25% of oxygen 
rich blood supply from hepatic artery, and the rest of the blood 
supply is from portal vein (1). Thus, targeting the transcription 
factor HIF-1α is a promising strategy as it exerts a crucial role in 
the balance between Th17 and Treg cells (81). HIF-1α predomi-
nantly affects effector T cell metabolism compared with Treg, thus 
there is a shift in immune cells balance under hypoxic conditions 
(82). HIF-1α and aryl hydrocarbon receptor (AhR) compete for 
limited amounts of aryl hydrocarbon receptor nuclear transloca-
tor (ARNT) also know as HIF-1β. This competition is the key 
to the mutual regulation of HIF-1α and AhR (83) (Figure  1). 
ARNT serves as a common binding partner for AhR as well as 
HIF-1α. HIF-1α proteins are regulated in an oxygen-dependent 
manner, whereas ARNT is constitutively expressed, as neither 
ARNT mRNA nor the protein level is influenced by hypoxia. 
In the context of transcription factor, HIF-1α induces FoxP3, 
which leads to Treg-cell abundance, and Treg-intrinsic HIF-1α 
is required for optimal Treg function (84). HIF-1α-deficient Treg 
cells fail to control T-cell-mediated colitis (84).
HIF-1α is selectively expressed in Th17 cells, and its induc-
tion requires signaling through mTOR, a central regulator of 
glycolytic metabolism. Therefore, blocking glycolysis inhibited 
Th17  cell development while it promotes Treg-cell generation 
(39). Lack of HIF-1α in  vivo has been reported to diminish 
Th17 cell development but enhance Treg-cell differentiation and 
prevent autoimmune neuroinflammation (39).
Metformin and 2-Deoxy-d-Glucose (2DG)
We reported that human liver infiltrating Treg cells are of an 
effector memory phenotype (16). However, intrahepatic Treg 
metabolic phenotype is still unexplored. When resting naive 
T cells are activated, they differentiate toward an effector T cell 
lineage due to a shift in the catabolic state of metabolism, 
which is driven predominantly by the glycolytic–lipogenic 
pathway through the TCA cycle. This upregulation of aerobic 
glycolysis, “Warburg effect,” is a feature of activated immune 
cells including T cells and is dependent on an mTOR–nutrient-
sensing pathway with signaling via phosphoinositide 3-kinase 
(PI3K) and protein kinase B (Akt) (85). In addition, CD4 T cell 
differentiation into the effector T  cell lineage toward Th1 or 
Th17 cell phenotypes is dependent on glucose and Glu for ana-
bolic metabolism. Recent study demonstrated that CD4 effector 
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T  cells from lupus-affected mice showed elevated glycolysis 
and mitochondrial oxidative metabolism and inhibition of 
these pathways with mitochondrial metabolism inhibitor met-
formin and the glucose metabolism inhibitor 2DG reduced IFNγ 
production (86). Furthermore, blocking glycolysis via 2DG 
can selectively impair effector T  cells thereby by improving 
Treg-cell function in a mouse model of multiple sclerosis (87). 
Antidiabetic medication, Metformin not only reduce Th17 cell 
responses and attenuates disease severity in experimental 
autoimmune encephalomyelitis (88) but also increase numbers 
of Treg cells via suppressing the activation of mTOR and its 
downstream target, HIF-1α (89). Thus, priming the T cells with 
Metformin may be an attractive option to shift the immune cell 
balance to the regulatory arm.
Soraphen A
Th17  cells, but not Treg cells, depend on ACC1 (acetyl CoA 
carboxylase 1), a key enzyme that drives FA synthesis and the 
underlying glycolytic–lipogenic metabolic pathway for their 
development. Treatment with the ACC-specific inhibitor 
Soraphen A or T cell-specific deletion of ACC1 in mice attenu-
ates Th17  cell-mediated autoimmune disease (90). Although 
Th17 cells use this pathway to produce phospholipids for cellular 
membranes, Treg cells readily take up exogenous FAs for this 
purpose. Pharmacologic inhibition or T cell-specific deletion of 
ACC1 not only blocks de novo FA synthesis but also interferes 
with the metabolic flux of glucose-derived carbon via glycolysis 
and the TCA cycle. Thus, the ACC1 pathway could be an attrac-
tive option to alter immune cell balance.
Phosphatase and Tensin Homolog (PTEN)
Phosphatase and tensin homolog lipid phosphatase is the main 
negative regulator of PI3K–Akt signaling and glycolysis in 
Treg cells. The activity of phosphoinositide-3-kinase (PI3K) 
is essential for Treg-cell lineage homeostasis and stability. 
Mechanistically, PTEN maintained Treg-cell stability and 
metabolic balance between glycolysis and mitochondrial fitness 
(91). Control of PI3K signaling by PTEN in Treg cells is critical 
for maintaining their homeostasis, function, and stability (92). 
PTEN deficiency upregulates activity of the metabolic check-
point kinase complex mTORC2, and the serine–threonine 
kinase Akt, and loss of this activity restores functioning of 
PTEN-deficient Treg cells. Thus, PTEN–mTORC2 axis main-
tains Treg-cell stability and coordinates Treg cell-mediated 
control of effector responses (91), and PTEN inhibitor can lead 
to Treg destabilization (93).
Targeting Lipid Metabolism
Mevalonate and Statins
Cholesterol lowering medications, statins are inhibitors of the 
enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, 
which catalyzes the formation of mevalonate, the rate-limiting 
step for cholesterol synthesis. As a result, statins are widely used 
for cardiovascular disease prevention. Statins can differentiate 
T cells toward Treg cells instead of Th17 cells via a mechanism 
dependent on protein granulation (94). In general, Treg cells 
require lipid and cholesterol metabolism. The mevalonate path-
way is particularly important for coordinating Treg proliferation 
and for upregulating the suppressive molecules CTLA-4 and 
ICOS to establish functional competency of Treg. Mevalonate 
can reverse the effects of statins involved in maintaining Treg 
functional fitness in an mTORC1-dependent manner (37) 
(Figure 3). Thus, mevalonate pathway could be manipulated to 
enhance Treg function in autoimmunity.
However, recent work from Hu and colleagues seems to con-
tradict this finding as they suggested that cholesterol biosynthesis 
and uptake programs are induced during Th17 differentiation, 
resulting in the accumulation of the cholesterol precursor, des-
mosterol, which functions as a potent endogenous RORγ agonist 
(95, 96). Thus, blocking cholesterol synthesis with chemical 
inhibitors at steps before the formation of active precursors would 
reduce differentiation to Th17. In addition, Simvastatin has also 
been shown to improve disease activity and the inflammation 
factor in patients with multiple sclerosis (97) and SLE (98). As 
there are conflicting data, more studies are required to dissect the 
mechanistic immunomodulatory effects of statins on Treg and 
Th17 cells.
Rapamycin and mTOR
The activation of mTOR, which is the catalytic subunit of the 
mTORC1 and mTORC2 complexes, delivers signals for the 
activation and differentiation of effector CD4 T cells, whereas 
Akt–mTOR axis is a crucial negative regulator of Treg de novo 
differentiation and expansion (Figure  3). mTORC1 signals 
through the TCR and the co-receptor CD28, and Treg cells 
have elevated steady-state mTORC1 activity compared with 
naive T  cells. Signals through the TCR and IL-2 provide 
major inputs for mTORC1 activation, which in turn programs 
the suppressive function of Treg (Figure  3). Disruption of 
mTORC1 through Treg-specific deletion of the essential com-
ponent raptor results in profound loss of Treg-cell suppressive 
activity and the development of a fatal early onset inflamma-
tory disorder (37). In addition, Raptor–mTORC1 signaling in 
Treg cells promotes cholesterol and lipid metabolism, with the 
mevalonate pathway particularly important for coordinating 
Treg-cell proliferation and upregulation of the suppressive 
molecules CTLA-4 and ICOS to establish Treg functional 
competency (Figure 3). Thus, mTORC1 acts as a “rheostat” in 
Treg cells to link immunological signals from TCR and IL-2 
to lipogenic pathways and functional fitness, and highlights 
a central role of metabolic programming of Treg suppressive 
activity in immune homeostasis and tolerance. All these data 
may lead investigators to reconsider and dissect the current use 
of rapamycin in good manufacturing practice (GMP) Treg-cell 
culture media (to prevent effector Th17  cells outgrowth) in 
Treg-cell therapy setting.
Peroxisome Proliferator-Activated Receptor (PPAR) 
Agonist—Pioglitazone
Peroxisome proliferator-activated receptors are nuclear receptors 
that regulate gene transcription. PPARα is highly expressed in 
liver and skeletal muscle and controls genes involved in fatty-acid 
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oxidation (99). PPARγ is expressed in adipocytes, skeletal mus-
cle, liver, and kidney and regulates expression of the genes that 
mediate metabolism (100). PPARγ agonists, thiazolidinedione 
drug pioglitazone, could potentially become an attractive drug 
candidate for anti-inflammatory therapies.
Targeting Protein Metabolism
Glu and α Ketoglutarate
Glutamine (Glu), a central anabolic nutrient in the TCA cycle, 
is critical for T cell survival, proliferation, and function. Glu is 
required for naive CD4 T  cell differentiation toward Th1 and 
Th17 inflammatory T  cells. In patients with multiple sclerosis, 
increased levels of both Glu and glutamate have been reported 
(101, 102). TCR engagement of naive CD4 T cells has been shown 
to trigger rapid uptake of Glu, via amino acid transporters. Glu 
deprivation has been shown to enhance the suppressive activity 
of Treg cells in an autoimmune colitis model (56). Thus, decline 
in Glu and α-ketoglutarate, Glu-derived TCA cycle metabolite 
could enhance Treg cells’ function.
BeNeFiTS AND SHORTCOMiNGS OF 
CURReNT TeCHNOLOGY
Both glycolysis and mitochondrial respiration can be studied 
using a Seahorse machine for immune cell subsets including 
peripheral blood CD4 and CD8 T cells. Extracellular acidifica-
tion rate (ECAR), a measure of lactate production by glycolysis, 
and mitochondrial oxygen consumption rate of both blood and 
tissue resident cells are necessary to analyze the metabolism 
and function of these cells. However, Seahorse technology is 
still not possible to apply for small frequency cell subset, such 
as regulatory T cells, to perform ECAR and OCAR experiments 
without cell expansion. However, expansion of the Treg will 
change their metabolic phenotype. Similarly, metabolic tracing 
with fluorescence uptake of glucose, Glu, lactate, or palmitate 
of Treg requires a significant number of cells. Thus, current 
available methodology to study tissue derived Treg is limited to 
Mitotracker and TMRE assays along with electron microscopy. 
In addition, comparing the metabolic activity of glycolysis and 
mitochondrial respiration in central memory (CD45RA−CCR7+), 
naïve (CD45RA+CCR7+), tissue resident (CD45RA+CCR7−), 
and effector memory (CD45RA−CCR7−) subsets of intrahepatic 
Treg cells is crucial to understand the metabolism and functional 
potential of each subset. However, investigators are limited to 
perform these analyses not by Seahorse technology but only by 
Mitotracker and TMRE assays along with electron microscopy 
due to the current requirement of high cell numbers. In addition, 
studies to assess tissue resident cell metabolism under hypoxic 
conditions and their migration would require a modified com-
bined technology of hypoxic chambers or migration chambers in 
combination with Seahorse equipment.
CONCLUSiON
T cell metabolism and immunology have recently been merged 
to form immunometabolism. Intrahepatic Treg cells can control 
local hepatic immune homeostasis. There is enormous potential 
to utilize Treg to restore tolerance in the treatment of human 
autoimmune diseases including autoimmune liver diseases. 
Modulation of immunometabolism of Treg represents a new 
avenue to enhance Treg-cell function and maintain a stable line-
age. Immunometabolic manipulation may also have an impact on 
Treg cytoskeletal rearrangement and post-endothelial migration, 
positioning around hepatocytes and bile ducts and retention as 
intrahepatic tissue resident Treg. However, to date, there are no 
data on human liver tissue resident Treg-cell metabolism. In the 
future, improvement of technology may allow us to study the 
metabolic profile and associated function Treg. Manipulating 
the cell culture media to enhance the metabolism of Treg dur-
ing GMP isolation and expansion and modulating the tissue 
and circulatory compartments with immunometabolic drugs in 
autoimmune patients before Treg infusion would enhance the 
potential of effective and successful Treg-cell therapy.
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